ARTICLE | Company News
Cambridge Antibody, Merck deal
October 15, 2001 7:00 AM UTC
CAT signed a five-year deal with MRK to develop therapeutics against a target involved in HIV-mediated diseases. CAT will use its human phage antibody libraries and MRK will contribute HIV biology res...